25 results about "Vaccine evaluation" patented technology

The invention provides an anti-varicella-zoster virus monoclonal antibody and an application thereof, relates to the technical field of monoclonal antibody screening and preparation, and more particularly relates to a monoclonal antibody which is obtained by immunizing mice through a recombinant varicella-zoster virus gE trimer protein vaccine. The monoclonal antibody for resisting the varicella-zoster virus is screened and prepared in a hybridoma mode, and the specific application of the antibody is provided. The recombinant VZV-gE tripolymer protein vaccine provided by the invention has good immunogenicity, and can induce higher immune serum titer. The human-mouse chimeric monoclonal antibody disclosed by the invention has good binding activity and affinity to the VZV-gE protein, and the indirect ELISA method for detecting the gE protein has good linear relation and detection limit, so that the human-mouse chimeric monoclonal antibody is expected to be used for VZV vaccine evaluation and VZV infection diagnosis.

The invention discloses an RSV infection immortalized tree shrew aorta vascular endothelial cell model, and particularly relates to a method for separating and culturing primary aorta vascular endothelial cells from tree shrew aorta, further establishing an immortalized tree shrew aorta vascular endothelial cell line, taking the cell line as an RSV virus culture medium, and constructing an RSV infection immortalized tree shrew aorta vascular endothelial cell model. Establishing an RSV infected immortalized tree shrew aortic vascular endothelial cell model, and preparing a high-infection-titer RSV virus; the invention provides key support for preparation and detection of RSV virus and construction of a tree shrew in-vivo infection model, provides a stable virus source for development of comparative medical research or vaccine evaluation, and has far-reaching significance for deep exploration of RSV pathogenic mechanism, drug and vaccine evaluation and the like.

The invention discloses a preparation method and application of a bovine tongue mucous membrane organoid, and relates to the technical field of organoid separation and culture. The preparation method of the ox tongue mucosa organoid comprises the following steps: treating fetal ox tongue tip tissues with digestive enzymes Dispase I, Collagenase II and Collagenase IV, separating ox tongue mucosa, cutting into pieces, treating again with pancreatin, and sieving to remove tissues and impurities; and continuously culturing by adopting a three-dimensional culture technology-matrigel embedding method and an organoid culture medium to obtain the final ox tongue mucous membrane organoid. The ox tongue mucous membrane organoid prepared by the preparation method disclosed by the invention has normal cell proliferation, differentiation and metabolism functions, and can be stably passaged under an in-vitro culture condition; the method can be widely applied to various related scientific researches such as FMDV infection mechanism research, drug screening and vaccine evaluation.

The invention provides a coxsackie virus group B type 2 strain and application thereof, and relates to the technical field of biological medicine. The strain is named as KM31-C05, and is preserved in the China Center for Type Culture Collection on May 16, 2025, the preservation number is CCTCC NO: V202541, and the preservation address is Wuhan University, Wuhan, China. The virus strain is a human coxsackie virus group B type 2 wild type single purified virus strain, and the virus strain is high in virus replication capacity and good in hereditary stability and immunogenicity; the virus strain can be applied to development of a production virus seed of a human coxsackie virus group B type 2 vaccine, and is suitable for development of an attenuated coxsackie virus group B type 2 vaccine and an inactivated coxsackie virus group B type 2 vaccine; the method is used for CVB2 infection and pathogenic mechanism research, CVB2 vaccine evaluation and antiviral drug screening.

This invention relates to the technical field of multi-channel ELISA reaction plates for detecting feline triple vaccine antibodies. It discloses a multi-channel ELISA reaction plate for detecting feline triple vaccine antibodies, comprising a reaction plate body, a base plate, and an ELISA reaction plate disposed on top of the base plate. The ELISA reaction plate has an FPV reaction channel, an FCV reaction channel, and an FHV reaction channel disposed on top of the ELISA reaction plate, and an ELISA plate sealing cap is snapped onto the top of the ELISA reaction plate. This invention enables multi-channel parallel reactions in the detection of feline triple vaccine antibodies, saving reagents, improving experimental efficiency, and is suitable for animal experiments, vaccine evaluation, and clinical sample testing. It is also sealable, stackable, and easy to transport.

The invention discloses a construction method and application of a hepatitis D virus replication mouse model. Experiments prove that the generation of HDV RNA and the expression of HDAg protein in mouse liver tissues can be maintained by performing caudal vein high-pressure injection on the pSVL (D3) plasmid. The invention provides a novel mouse model for HDV research, provides a new in-vivo platform for anti-HDV drug screening and vaccine evaluation, and has wide application prospects and market potential.

The invention discloses a porcine rotavirus VP4 protein monoclonal antibody, a kit and application, and belongs to the field of porcine rotavirus antibody detection. The porcine rotavirus VP4 protein monoclonal antibody comprises a heavy chain and a light chain, the amino acid sequence of the heavy chain is shown as SEQ ID NO. 1, and the amino acid sequence of the light chain is shown as SEQ ID NO. 2. According to the present invention, the blocking ELISA detection kit and the detection method are innovatively constructed by using the monoclonal antibody targeting the VP4 conserved functional epitope as the core, and the method can significantly reduce the cross reaction and truly reflect the protective immune level; compared with the prior art, the method provided by the invention has the advantages of no need of species-specific secondary antibody, avoidance of non-specific binding and serum source interference, strong universality, good repeatability and suitability for high-throughput application, fills the technical blank, and provides a novel tool with high specificity, high correlation and high practicability for precise immune monitoring and vaccine evaluation of PoRV.

The present invention discloses a humanized animal model for human influenza virus infection and a preparation method. The present invention provides a method for constructing a mouse model for human influenza virus infection, comprising the following steps: introducing the endothelial cell-specific promoter K18, the human sialyltransferase ST6GAL1 encoding gene, and the luciferase encoding gene into wild-type mice; subsequently breeding to obtain the F2 generation, which is a mouse model for human influenza virus infection; and each generation is subjected to genotyping and in vivo imaging identification. The present invention inserts the human ST6GAL1 gene into the mouse gene sequence, overexpresses the human sialyltransferase ST6GAL1 that synthesizes the human α2,6-linked sialic acid receptor, and constructs a mouse model for human influenza virus infection. The model can be directly infected with human influenza virus without the need for an in vivo adaptation process in mice, providing a humanized mouse model that conforms to the clinical characteristics of influenza for in-depth elucidation of the pathogenesis of influenza, verification of new drug targets, and development of new drugs and vaccine evaluation.

The invention discloses an immune effect evaluation method of an avian adenovirus 11 vaccine, and belongs to the technical field of vaccine evaluation. According to the method, immune antibodies are obtained after breeding hens are used for immunizing the fowl adenovirus 11 vaccine, then the immune antibodies are transmitted to fertilized eggs and hatched offspring chicks through passive immunization, the offspring chicks passively obtain maternal antibodies, the offspring chicks are used for counteracting toxic substances, and the fowl adenovirus 11 vaccine is obtained. Meanwhile, the death condition and / or clinical symptoms of the immune offspring chicks after challenge are / is taken as an index, or the death condition and / or inclusion body hepatitis symptoms after dissection of the immune offspring chicks after challenge are / is taken as an index, or the virus load in liver tissues of the immune offspring chicks after challenge is taken as an index; the method can be used for efficiently, quickly and accurately evaluating the fowl adenovirus 11 type vaccine. Therefore, the method for evaluating the immune effect of the fowl adenovirus type 11 vaccine has a relatively good application value.

The invention belongs to the technical field of microbial immunity and DNA vaccines, and particularly relates to a preferred epitope peptide of a Crimean-Congo hemorrhagic fever virus envelope glycoprotein C terminal (CCHFV Gc), a tandem multi-epitope vaccine, an expression vector and application. The preferable epitope peptide is composed of any one amino acid sequence as shown in SEQ ID NO.1-SEQ ID NO.21, and the preferable epitope peptide has high affinity, strong immunogenicity and interspecific amp; and an intraspecific conservative preferred epitope. Preferably epitopes are connected in series through a linker to synthesize a series multi-epitope vaccine, the series multi-epitope vaccine enters cells to be expressed to form recombinant protein, then T lymphocytes are activated, and cellular immune response is induced. The in-vivo vaccine evaluation of animals is carried out by using the tandem multi-epitope vaccine, and it is proved that the vaccine can effectively induce anti-CCHFV specific cellular immune response and the application safety in BALB / c mice. The invention is helpful for understanding the immunobiology of CCHFV Gc and perfecting the epitope vaccine design for the virus in the future.

The invention relates to a type II herpes simplex virus strain HSV-2 / KM-1 and application thereof, and belongs to the technical field of virus microorganisms. The II-type herpes simplex virus strain HSV-2 / KM-1 is preserved in the China Center for Type Culture Collection on July 25, 2025, and the preservation number of the II-type herpes simplex virus strain HSV-2 / KM-1 is CCTCC (China Center for Type Culture Collection) NO: V202550. The II-type herpes simplex virus strain HSV-2 / KM-1 disclosed by the invention has cell tropism and tends to infect genital epithelial cells; the II-type herpes simplex virus strain HSV-2 / KM-1 is applied to neutralizing antibody detection of mouse serum, and the instrumental effect of the II-type herpes simplex virus strain HSV-2 / KM-1 in immunogenicity evaluation of vaccines is disclosed. According to the invention, the II-type herpes simplex virus strain HSV-2 / KM-1 is simultaneously utilized to successfully construct a Hartley guinea pig genital herpes model or a BALB / c mouse genital herpes model, and the models can be used as new tools for HSV-2 vaccine evaluation.

The application discloses a monoclonal antibody of a porcine rotavirus VP6 protein, an epitope of the monoclonal antibody and application of the monoclonal antibody. The monoclonal antibody can specifically recognize a linear B cell epitope on the VP6 protein, and a core sequence of the epitope is TTRLSFQLVR. The antibody has high affinity and high specificity, and can cross-react with porcine rotaviruses of various genotypes such as G5, G9 and G11. The application further includes an indirect ELISA detection kit containing the monoclonal antibody, and application of the linear epitope in detection of porcine rotaviruses, development of vaccines and research on functions of viral proteins. The application provides an important tool and theoretical basis for serological diagnosis, vaccine evaluation and etiological research of porcine rotaviruses.

The invention provides a coxsackie virus group B type 3 strain and application thereof, and relates to the technical field of biological medicine. The strain is named as KM50-W07, and is preserved in the China Center for Type Culture Collection on November 6, 2024, the preservation number is CCTCC NO: V202474, and the preservation address is Wuhan University, Wuhan, China. The virus strain is a human coxsackie virus group B type 3 wild type single purified virus strain, and the virus strain is high in virus replication capacity and good in hereditary stability and immunogenicity; the virus strain can be applied to development of a production virus seed of a human coxsackie virus group B type 3 vaccine, and is suitable for development of an attenuated coxsackie virus group B type 3 vaccine and an inactivated coxsackie virus group B type 3 vaccine; and an infection model can be established on Vero cells and suckling mice and is used for CVB3 infection and pathogenic mechanism research, CVB3 vaccine evaluation and antiviral drug screening.

The invention discloses a construction method and application of a mouse hepatic echinococcosis granulosis cyst model, and relates to the technical field of biology. The construction method comprises the following steps: under the guidance of B ultrasound, carrying out liver envelope injection on a mouse, injecting an echinococcus granulosus protoscolex into liver parenchyma through envelope puncture, and carrying out feeding and cystic focus screening to obtain the mouse liver echinococcus granulosus model. According to the invention, a percutaneous liver membrane injection method under the guidance of B ultrasound is adopted for the first time, and an injection site is accurately positioned under the monitoring of a real-time image, so that the colonization rate of an original head section in the liver is remarkably improved, and meanwhile, the risk of operative trauma and abdominal cavity dissemination is avoided. The method disclosed by the invention is simple and convenient to operate, low in injury, short in time consumption, high in success rate, controllable in focus position and size and good in repeatability. Besides, according to the method, mechanical injuries to the liver and other visceral organs are greatly reduced, the inflammatory reaction and rejection risks are reduced, and a more reliable animal model is provided for pathogenesis research, drug screening and vaccine evaluation of the echinococcosis granulosa.

The application belongs to the field of biology and discloses a rabbit-derived monoclonal antibody against chicken IFN-gamma protein, which contains a heavy chain variable region and a light chain variable region; the amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown as SEQ ID No. 1; and the amino acid sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID No. 2. The rabbit-derived monoclonal antibody is named Ab-56, and has the following characteristics: 1. Compared with existing monoclonal antibodies, the rabbit-derived monoclonal antibody has strong binding capacity with interferon; 2. The rabbit-derived monoclonal antibody also has strong binding capacity with duck interferon. This provides a solid foundation for evaluation of immune protection effect of some mRNA vaccines, DNA vaccines or live virus vector vaccines and research on immune response mechanism caused by virus infection, and the rabbit-derived monoclonal antibody is not only suitable for chickens, but also suitable for ducks and even other poultry for research on vaccine evaluation and cellular immune protection mechanism. In addition, the application also provides the monoclonal antibody and application.

The invention discloses a B cell conservative epitope peptide on self-transcription protein A (LatA) of porcine intracellular Lawsonia suis (LI) and application of the B cell conservative epitope peptide in LI specific antibody diagnosis. The sequence of the B cell conservative epitope peptide of the LatA is NGNGNPAN, and the B cell conservative epitope peptide of the LatA is named as NN8. The B cell conservative epitope peptide can be functionally displayed and expressed on the surface of an inert carrier S9H thallus, an NN8-antibody direct mediated agglutination test established on the basis of S9H thallus surface display and expression is adopted, and NN8 specifically recognizes an LI antibody and has no cross reaction with serum antibodies of other swine infectious diseases. Animal test results show that the method can detect the specific serum antibody 7 days after the Balb / c mouse is infected by the attenuated strain and immunized by the vaccine. The diagnosis method is high in specificity, good in sensitivity, convenient to operate and visual in result judgment, and is expected to become a technical means for LI infection visual on-site accurate and convenient diagnosis and vaccine evaluation.

The invention discloses a mouse model infected with coxsackie virus A16 and a construction method of the mouse model, and the construction method comprises the following specific steps: connecting a left homologous arm LHA of a Rosa26 site to a plasmid pCAG-GFP-N1, and successfully constructing the plasmid pCAG-GFP-N1-Rosa26 LHA. Then carrying out PCR (Polymerase Chain Reaction) amplification on the Rosa26-RHA fragment, the hSCARB2 fragment and the wpre-polyA fragment by using a high-fidelity enzyme; the preparation method comprises the following steps: carrying out enzyme digestion by using Hind3, recovering a large fragment as a connecting vector for later use, and successfully constructing the three fragments onto the vector by using a Gibson Assembly one-step method, thereby obtaining the required target vector pmRosa26-CAG-hSCARB2. Then mixing the target vector with targeted sgRNA and Cas9 mRNA, co-injecting the mixture into a fertilized egg of a C57 mouse, then transplanting the fertilized egg into a fallopian tube of a pseudopregnant ICR female mouse, and finally obtaining an hSCARB2 fixed point (Rosa26) knock-in mouse. Through intracranial injection of the CVA-16 virus, the result proves that the knock-in mouse can be successfully infected with the CVA-16 virus at the age of 10 days, 21 days and 30 days, and the model has serious phenomena such as posterior limb paralysis and death for the first time, so that a powerful tool is provided for vaccine evaluation and drug screening.

The application discloses a mouse-adapted coxsackievirus A4 strain and a construction method of an infection model thereof, the virus strain has a preservation number of CCTCC NO:V202432, and an ICR mouse hand-foot-mouth disease infection model of 13 days old is established by using the virus strain, and the mouse hand-foot-mouth disease infection model can present similar pathological changes to human diseases, especially hand-foot-mouth disease. Compared with the previous mouse model of less than 7 days old, the mouse hand-foot-mouth disease infection model constructed by the application solves the defects of difficult drug administration, low drug administration volume and the like of the small-day-old mouse, so that the mouse model can be applied to long-time drug efficacy observation and vaccine evaluation, and the model has very important application value in researches on the pathogenesis of HFMD, the effectiveness evaluation of vaccines, the screening and drug efficacy evaluation of antiviral drugs and the like. The application solves the technical problems that the coxsackievirus A4 strain is used to establish a model by using 1 to 7 day-old mice at present at home and abroad, and the day-old mice are small in age, difficult to administer drugs, and the infection model is not easy to prepare successfully.

The invention discloses a method for preparing a feline calicivirus pseudovirus. The method comprises the following steps: first obtaining the gp2 gene by PCR amplification, then constructing an entry cloning vector pDown-{FCV-gp2} containing the gp2 gene sequence by BP reaction, and then recombining the promoter-carrying pUp-EF1A vector, pDown-{FCV-gp2}, and pLV.Des2d.C / EGFP:T2A:Puro by LR reaction to obtain a recombinant expression vector pLV[Exp]-EGFP:T2A:Puro-EF1A>{FCV-gp2}, which is then co-transfected with a lentiviral packaging plasmid into HEK293T cells. The feline calicivirus pseudovirus prepared by the method has no replication activity, high biosafety, and can provide a powerful screening tool for feline calicivirus research, antiviral preparations, and vaccine evaluation, with wide application value.

The invention provides a reverse pseudovirus particle based on a receptor as well as a preparation method and application of the reverse pseudovirus particle, and belongs to the technical field of biological pharmacy. A transmembrane protein receptor derived from a host is integrated on an envelope of the pseudovirus particle, and an extracellular structural domain of the transmembrane protein receptor faces the outside of the virus particle, so that the pseudovirus particle can specifically recognize and combine target cells expressing corresponding virus envelope protein, and the pseudovirus particle is mediated to enter the target cells. The skeleton of the pseudovirus particle is selected from one of VSV [delta] G, HIV or MLV. The transmembrane protein receptor is I-type transmembrane protein, and is preferably selected from ACE2, DPP4 or APN. According to the invention, a prefabricated and extensible reverse receptor pseudovirus detection system is constructed, multi-receptor cross-species function evaluation and rapid new coronavirus receptor identification are realized, and an efficient and universal platform is provided for cross-species propagation monitoring, drug screening and vaccine evaluation.

The application discloses a porcine rotavirus VP4 protein monoclonal antibody, a kit and application, and belongs to the field of porcine rotavirus antibody detection.The porcine rotavirus VP4 protein monoclonal antibody comprises a heavy chain and a light chain, the amino acid sequence of the heavy chain is shown as SEQ ID NO.1, and the amino acid sequence of the light chain is shown as SEQ ID NO.2.Innovatively taking the monoclonal antibody targeting a VP4 conservative functional epitope as the core, an ELISA detection kit and a detection method are constructed, the method can significantly reduce cross-reactions, and can truly reflect a protective immune level;without a species-specific secondary antibody, non-specific binding and serum source interference are avoided, the method has strong universality, good repeatability, is suitable for high-throughput application, and fills a technical blank, and provides a new tool with high specificity, high correlation and high practicability for precise immune monitoring and vaccine evaluation of PoRV.

The invention discloses a monoclonal antibody of porcine rotavirus VP6 protein, an epitope of the monoclonal antibody and application of the monoclonal antibody, the monoclonal antibody can specifically recognize linear B cell epitopes on the VP6 protein, and the epitope core sequence of the monoclonal antibody is TTRLSFQLVR. The antibody has high affinity and high specificity, and can be subjected to cross reaction with various genotypes of porcine rotaviruses such as G5, G9, G11 and the like. The invention also comprises an indirect ELISA detection kit containing the monoclonal antibody, and application of the linear epitope in porcine rotavirus detection, vaccine research and development and virus protein function research. The invention provides an important tool and theoretical basis for serological diagnosis, vaccine evaluation and etiological research of the porcine rotavirus.

The invention belongs to the field of biology, and discloses a rabbit monoclonal antibody for resisting chicken IFN-gamma protein, the rabbit monoclonal antibody contains a heavy chain variable region and a light chain variable region; the amino acid sequence of a heavy chain variable region of the monoclonal antibody is as shown in SEQ ID No.1; the amino acid sequence of the light chain variable region of the monoclonal antibody is as shown in SEQ ID No.2. The rabbit monoclonal antibody is named Ab-56, and has the following characteristics: 1, compared with the existing monoclonal antibody, the rabbit monoclonal antibody has very strong binding capacity with interferon; and 2, the compound also has very strong combining capacity with duck interferon. Therefore, a solid foundation is provided for evaluation of immune protection effects generated by novel vaccines such as mRNA vaccines, DNA vaccines or live virus vector vaccines and research on immune reaction mechanisms caused by virus infection, and meanwhile, the method is not only suitable for vaccine evaluation of chickens, but also suitable for vaccine evaluation of ducks and even other poultry and research on cellular immune protection mechanisms. Meanwhile, the invention also provides a monoclonal antibody and application.

The invention discloses a primer combination and a kit for obtaining a whole genome sequence of a porcine reproductive and respiratory syndrome virus American type strain and application of the primer combination and the kit. The primer combination can realize full coverage of a genome of the porcine reproductive and respiratory syndrome virus American type strain; in addition, the coverage rate of the primer combination on porcine reproductive and respiratory syndrome virus sequences in Asian areas in recent 10 years is far higher than that of an existing primer combination, and the reliability and the universality of complete acquisition of the genome of the American type strains of the porcine reproductive and respiratory syndrome are greatly improved. The invention provides a method for quickly acquiring the whole genome sequence of the porcine reproductive and respiratory syndrome virus, and provides a solid technical basis for advanced applications such as precise typing, traceability, virulence / immune escape analysis, vaccine evaluation, variation monitoring and the like based on the whole genome. The method can realize rapid tracing of blue ear pathogens, and has a wide application prospect.